Results 21 to 30 of about 12,197,984 (249)

Weekly long-acting growth hormone versus daily growth hormone therapy on quality of life, efficacy, and safety in children with short stature: a systematic review and meta-analysis [PDF]

Frontiers in Endocrinology
BackgroundThis meta-analysis aims to compare the QoL, efficacy, and safety of once-weekly LAGH versus daily GH in children with short stature.MethodsWe systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to ...
Fan Liu, Linying Xiu, Wei Zhang, Chunhui Zang, Shuyu Wang   +4 more
doaj   +2 more sources

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency

Endocrine Connections, 2017
TransCon growth hormone is a sustained-release human growth hormone prodrug under development in which unmodified growth hormone is transiently linked to a carrier molecule.
Charlotte Höybye, Andreas F H Pfeiffer, Diego Ferone, Jens Sandahl Christiansen, David Gilfoyle, Eva Dam Christoffersen, Eva Mortensen, Jonathan A Leff, Michael Beckert   +8 more
doaj   +2 more sources

Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients [PDF]

Frontiers in Pediatrics
ObjectiveTo comprehensively compare the efficacy and safety of long-acting human growth hormone (LAGH) preparations with conventional short-acting daily growth hormone (SA-GH) in children with isolated growth hormone deficiency (GHD), and explore ...
Zhen-Zhen Shen, Yun Huang, Li-Li Wu, Jian-Su Zhang, Xiao-Xia Zhang   +4 more
doaj   +2 more sources

Long-acting growth hormone therapy in paediatric growth hormone deficiency: reduced treatment burden and unproven motivation-related neuroendocrine effects [PDF]

Frontiers in Endocrinology
Long-acting growth hormone (LAGH) formulations represent an important therapeutic advance in the management of growth hormone deficiency (GHD) because they reduce injection frequency and treatment burden and may improve adherence and patient-reported ...
Rossella Gaudino, Franco Antoniazzi, Marco Zaffanello, Angelo Pietrobelli, Angelo Pietrobelli, Thomas Zoller, Ruggero Lanzafame, Giorgio Piacentini   +7 more
doaj   +2 more sources

The current state of long-acting growth hormone preparations for growth hormone therapy

Current Opinion in Endocrinology, Diabetes & Obesity, 2018
Purpose of review To discuss the rationale of developing long-acting growth hormone (LAGH) preparations, to describe the technologies designed to prolong GH action, and to address key issues regarding efficacy, safety, and monitoring while on treatment.
Kevin C J, Yuen, Bradley S, Miller, Beverly M K, Biller   +2 more
openaire   +3 more sources

Long-acting growth hormone: an updated Growth Hormone Research Society consensus statement

European Journal of Endocrinology
Abstract Long-acting growth hormone (LAGH) preparations have moved from development to routine clinical use over the past decade. Several products are now approved for paediatric growth hormone deficiency (GHD), selected non-GHD short-stature indications, and, in some regions, for adult GHD.
Schilbach, Katharina, Clayton, Peter, Agrawal, Nidhi, Arlien-Søborg, Mai, Backeljauw, Philippe, Biller, Beverly, Boguszewski, Cesar, Boguszewski, Margaret, Chanson, Philippe, Chatelain, Pierre, Cianfarani, Stefano, Fleseriu, Maria, Gebauer, Judith, Grimberg, Adda, Ho, Ken, Hoffman, Andrew, Johannsson, Gudmundur, Jorgensen, Jens, Juul, Anders, Karges, Wolfram, Lebl, Jan, Luo, Xiaoping, Maghnie, Mohamad, Maniatis, Aristides, Miller, Bradley, Neggers, Sebastian, Polak, Michel, Radovick, Sally, Sävendahl, Lars, Schweizer, Junia, Collett-Solberg, Paulo, Stevens, Adam, Strasburger, Christian, van Bunderen, Christa, Werner, Haim, Woelfle, Joachim, Yuen, Kevin, Bidlingmaier, Martin   +37 more
core   +4 more sources

New directions in growth hormone treatment in children

Pediatric Endocrinology, Diabetes and Metabolism
This paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin,
Renata Stawerska
doaj   +2 more sources

Editorial: Long-acting growth hormone therapy in pediatric growth hormone deficiency [PDF]

Frontiers in Endocrinology
Anastasia Ibba, Giuseppa Patti, Giuseppa Patti, Sandro Loche   +3 more
doaj   +2 more sources

Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis [PDF]

Scientific Reports
The purpose of this study is to compare the relative efficacy and safety of long-acting growth hormone (LAGH) as a growth hormone replacement therapy in prepubertal children with growth hormone deficiency (GHD).
Jianfang Zhu, Ke Yuan, Sunita Rana, Satya Lavanya Jakki, Amit Subray Bhat, Li Liang, Chunlin Wang   +6 more
doaj   +2 more sources

Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone [PDF]

Children
Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat,
Atilla Büyükgebiz, And Demir
doaj   +2 more sources